mergers & acquisitions
Freeline Therapeutics Acquires SwanBio Therapeutics, Rebrands as New Gene Therapy Company
The new company, Spur Therapeutics, will continue to advance existing gene therapy candidates while pivoting its focus to chronic conditions.
Reneo Pharmaceuticals, OnKure to Merge in All-Stock Transaction, Advance PI3Kα Inhibitors
In connection with the merger, Reneo entered into a $65 million private investment in public equity financing with a group of institutional investors.
With Seagen integrated into its business, Pfizer has new sources of revenue and forthcoming data readouts on precision oncology drugs.
OmnigenicsAI, MultiplAI Health to Merge, Go Public in $340M SPAC Deal
The transaction, which is expected to close midyear, will result in OmnigenicsAI becoming publicly traded on the Nasdaq under the ticker symbol OMNI.
Kinnate Biopharma Sells RAF inhibitor Exarafenib to Pierre Fabre Laboratories for $31M
Kinnate began seeking strategic alternatives for exarafenib in September after deprioritizing a monotherapy trial of the drug.
Feb 6, 2024
Jan 8, 2024
Merck to Acquire Harpoon Therapeutics for $680M
Jan 8, 2024
J&J to Acquire Ambrx Biopharma for Around $2B
Dec 27, 2023
Bristol Myers Squibb Acquires RayzeBio for $4.1B
Dec 14, 2023